DIA 2015 Annual Meeting, Washington, D.C. and Boston, Mass. – June 16, 2015 –BBK Worldwide, a leading clinical trial marketing firm, has appointed Toshio Mori to Managing Director of Operations, Japan. Mori will lead business development and help drive sales and marketing in Japan, and will report to BBK Principal, Global Resources Steven Fleishman. Mori is also responsible for establishing and growing the company’s new Japan office, based in Tokyo.
Mori brings more than 25 years of pharmaceutical and medical device experience to the role. Before BBK, Mori established and then led operations at Japan-based Candela KK, a subsidiary of Syneron-Candela, a global market leader in the aesthetic medical device marketplace. Earlier in his career, he held senior sales and marketing positions at Sansui Electronic Co.
“Toshio’s expertise across a broad set of disease areas – from cancer to neurological disorders – combined with his established leadership among physicians and study investigators will help us further extend our global reach and support the increased demand for clinical research in Japan,” said Fleishman. “We remain committed to expanding our support in Japan, and are happy to be entering this new phase of growth with Toshio’s support.”
“I was drawn to BBK for its leadership in patent recruitment and engagement, as well as its commitment to patient centricity and diversity,” said Mori. “I’m pleased to be joining the distinguished team and look forward to advancing the company’s work in Japan.”
With deep experience across many multinational patient recruitment and retention campaigns, BBK has worked with eight of the top 10 pharmaceutical companies in Japan, since opening its original Japan office in Osaka. The company’s recruitment and engagement software solutions, consulting services and integrated cloud-based infrastructure supports proactive contingency action planning through access to real-time recruitment data tracking and management, and offers critical interfaces for referral management and enrollment reporting for Japan audiences.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.